<?xml version='1.0' encoding='utf-8'?>
<document id="23712757"><sentence text="Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin."><entity charOffset="57-67" id="DDI-PubMed.23712757.s1.e0" text="danoprevir" /><entity charOffset="69-78" id="DDI-PubMed.23712757.s1.e1" text="ritonavir" /><entity charOffset="143-154" id="DDI-PubMed.23712757.s1.e2" text="ciclosporin" /><pair ddi="false" e1="DDI-PubMed.23712757.s1.e0" e2="DDI-PubMed.23712757.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23712757.s1.e0" e2="DDI-PubMed.23712757.s1.e1" /><pair ddi="false" e1="DDI-PubMed.23712757.s1.e0" e2="DDI-PubMed.23712757.s1.e2" /><pair ddi="false" e1="DDI-PubMed.23712757.s1.e1" e2="DDI-PubMed.23712757.s1.e1" /><pair ddi="false" e1="DDI-PubMed.23712757.s1.e1" e2="DDI-PubMed.23712757.s1.e2" /></sentence><sentence text="Danoprevir (RG7227) is a potent macrocyclic inhibitor of the hepatitis C virus NS3/4A protease, which is currently in development in combination with low-dose ritonavir for the treatment of chronic hepatitis C infection"><entity charOffset="0-10" id="DDI-PubMed.23712757.s2.e0" text="Danoprevir" /><entity charOffset="159-168" id="DDI-PubMed.23712757.s2.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.23712757.s2.e0" e2="DDI-PubMed.23712757.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23712757.s2.e0" e2="DDI-PubMed.23712757.s2.e1" /></sentence><sentence text=" Danoprevir is a substrate of cytochrome P450 3A4, and the organic anion transporting polypeptides (OATP) 1B1 and 1B3"><entity charOffset="1-11" id="DDI-PubMed.23712757.s3.e0" text="Danoprevir" /></sentence><sentence text="" /><sentence text="The objective of this study was to evaluate the effect of a potent OATP inhibitor, ciclosporin, on danoprevir pharmacokinetics, when administered as danoprevir/ritonavir"><entity charOffset="83-94" id="DDI-PubMed.23712757.s5.e0" text="ciclosporin" /><entity charOffset="99-109" id="DDI-PubMed.23712757.s5.e1" text="danoprevir" /><entity charOffset="149-159" id="DDI-PubMed.23712757.s5.e2" text="danoprevir" /><entity charOffset="160-169" id="DDI-PubMed.23712757.s5.e3" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.23712757.s5.e0" e2="DDI-PubMed.23712757.s5.e0" /><pair ddi="false" e1="DDI-PubMed.23712757.s5.e0" e2="DDI-PubMed.23712757.s5.e1" /><pair ddi="false" e1="DDI-PubMed.23712757.s5.e0" e2="DDI-PubMed.23712757.s5.e2" /><pair ddi="false" e1="DDI-PubMed.23712757.s5.e0" e2="DDI-PubMed.23712757.s5.e3" /><pair ddi="false" e1="DDI-PubMed.23712757.s5.e1" e2="DDI-PubMed.23712757.s5.e1" /><pair ddi="false" e1="DDI-PubMed.23712757.s5.e1" e2="DDI-PubMed.23712757.s5.e2" /><pair ddi="false" e1="DDI-PubMed.23712757.s5.e1" e2="DDI-PubMed.23712757.s5.e3" /><pair ddi="false" e1="DDI-PubMed.23712757.s5.e2" e2="DDI-PubMed.23712757.s5.e2" /><pair ddi="false" e1="DDI-PubMed.23712757.s5.e2" e2="DDI-PubMed.23712757.s5.e3" /></sentence><sentence text=" The effect of danoprevir/ritonavir on ciclosporin pharmacokinetics was also investigated"><entity charOffset="15-25" id="DDI-PubMed.23712757.s6.e0" text="danoprevir" /><entity charOffset="26-35" id="DDI-PubMed.23712757.s6.e1" text="ritonavir" /><entity charOffset="39-50" id="DDI-PubMed.23712757.s6.e2" text="ciclosporin" /><pair ddi="false" e1="DDI-PubMed.23712757.s6.e0" e2="DDI-PubMed.23712757.s6.e0" /><pair ddi="false" e1="DDI-PubMed.23712757.s6.e0" e2="DDI-PubMed.23712757.s6.e1" /><pair ddi="false" e1="DDI-PubMed.23712757.s6.e0" e2="DDI-PubMed.23712757.s6.e2" /><pair ddi="false" e1="DDI-PubMed.23712757.s6.e1" e2="DDI-PubMed.23712757.s6.e1" /><pair ddi="false" e1="DDI-PubMed.23712757.s6.e1" e2="DDI-PubMed.23712757.s6.e2" /></sentence><sentence text="" /><sentence text="This was a single-dose, randomized, open-label, two-sequence, three-period, crossover study in healthy volunteers" /><sentence text=" In the first period, subjects were randomized to receive either a single oral dose of danoprevir 100 mg in combination with ritonavir 100 mg or a single oral dose of ciclosporin 100 mg"><entity charOffset="87-97" id="DDI-PubMed.23712757.s9.e0" text="danoprevir" /><entity charOffset="125-134" id="DDI-PubMed.23712757.s9.e1" text="ritonavir" /><entity charOffset="167-178" id="DDI-PubMed.23712757.s9.e2" text="ciclosporin" /><pair ddi="false" e1="DDI-PubMed.23712757.s9.e0" e2="DDI-PubMed.23712757.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23712757.s9.e0" e2="DDI-PubMed.23712757.s9.e1" /><pair ddi="false" e1="DDI-PubMed.23712757.s9.e0" e2="DDI-PubMed.23712757.s9.e2" /><pair ddi="false" e1="DDI-PubMed.23712757.s9.e1" e2="DDI-PubMed.23712757.s9.e1" /><pair ddi="false" e1="DDI-PubMed.23712757.s9.e1" e2="DDI-PubMed.23712757.s9.e2" /></sentence><sentence text=" After a 14-day washout, patients were crossed over to receive the opposite treatment" /><sentence text=" In period 3, all subjects received the combination of danoprevir/ritonavir and ciclosporin following a 14-day washout from period 2"><entity charOffset="55-65" id="DDI-PubMed.23712757.s11.e0" text="danoprevir" /><entity charOffset="66-75" id="DDI-PubMed.23712757.s11.e1" text="ritonavir" /><entity charOffset="80-91" id="DDI-PubMed.23712757.s11.e2" text="ciclosporin" /><pair ddi="false" e1="DDI-PubMed.23712757.s11.e0" e2="DDI-PubMed.23712757.s11.e0" /><pair ddi="false" e1="DDI-PubMed.23712757.s11.e0" e2="DDI-PubMed.23712757.s11.e1" /><pair ddi="false" e1="DDI-PubMed.23712757.s11.e0" e2="DDI-PubMed.23712757.s11.e2" /><pair ddi="false" e1="DDI-PubMed.23712757.s11.e1" e2="DDI-PubMed.23712757.s11.e1" /><pair ddi="false" e1="DDI-PubMed.23712757.s11.e1" e2="DDI-PubMed.23712757.s11.e2" /></sentence><sentence text=" Blood samples were collected serially with each dose for pharmacokinetic assessment" /><sentence text=" Pharmacokinetic parameters were estimated using non-compartmental analysis" /><sentence text=" Geometric mean ratios (GMRs) and 90 % confidence intervals (CIs) were used to compare pharmacokinetic parameters [maximum concentration (C max), area under the concentration-time curve from time zero to infinity (AUC∞), and concentration 12 h post-dose (C 12h)] of danoprevir/ritonavir and ciclosporin when administered alone or in combination"><entity charOffset="266-276" id="DDI-PubMed.23712757.s14.e0" text="danoprevir" /><entity charOffset="277-286" id="DDI-PubMed.23712757.s14.e1" text="ritonavir" /><entity charOffset="291-302" id="DDI-PubMed.23712757.s14.e2" text="ciclosporin" /><pair ddi="false" e1="DDI-PubMed.23712757.s14.e0" e2="DDI-PubMed.23712757.s14.e0" /><pair ddi="false" e1="DDI-PubMed.23712757.s14.e0" e2="DDI-PubMed.23712757.s14.e1" /><pair ddi="false" e1="DDI-PubMed.23712757.s14.e0" e2="DDI-PubMed.23712757.s14.e2" /><pair ddi="false" e1="DDI-PubMed.23712757.s14.e1" e2="DDI-PubMed.23712757.s14.e1" /><pair ddi="false" e1="DDI-PubMed.23712757.s14.e1" e2="DDI-PubMed.23712757.s14.e2" /></sentence><sentence text=" Measures of safety and tolerability were also evaluated" /><sentence text="" /><sentence text="A total of 18 subjects were enrolled, and 17 completed the study" /><sentence text=" The C max, AUC∞, and C 12h GMRs (90 % CI) when danoprevir/ritonavir and ciclosporin were co-administered versus danoprevir/ritonavir or ciclosporin alone were 7"><entity charOffset="48-58" id="DDI-PubMed.23712757.s18.e0" text="danoprevir" /><entity charOffset="59-68" id="DDI-PubMed.23712757.s18.e1" text="ritonavir" /><entity charOffset="73-84" id="DDI-PubMed.23712757.s18.e2" text="ciclosporin" /><entity charOffset="113-123" id="DDI-PubMed.23712757.s18.e3" text="danoprevir" /><entity charOffset="124-133" id="DDI-PubMed.23712757.s18.e4" text="ritonavir" /><entity charOffset="137-148" id="DDI-PubMed.23712757.s18.e5" text="ciclosporin" /><pair ddi="false" e1="DDI-PubMed.23712757.s18.e0" e2="DDI-PubMed.23712757.s18.e0" /><pair ddi="false" e1="DDI-PubMed.23712757.s18.e0" e2="DDI-PubMed.23712757.s18.e1" /><pair ddi="false" e1="DDI-PubMed.23712757.s18.e0" e2="DDI-PubMed.23712757.s18.e2" /><pair ddi="false" e1="DDI-PubMed.23712757.s18.e0" e2="DDI-PubMed.23712757.s18.e3" /><pair ddi="false" e1="DDI-PubMed.23712757.s18.e0" e2="DDI-PubMed.23712757.s18.e4" /><pair ddi="false" e1="DDI-PubMed.23712757.s18.e0" e2="DDI-PubMed.23712757.s18.e5" /><pair ddi="false" e1="DDI-PubMed.23712757.s18.e1" e2="DDI-PubMed.23712757.s18.e1" /><pair ddi="false" e1="DDI-PubMed.23712757.s18.e1" e2="DDI-PubMed.23712757.s18.e2" /><pair ddi="false" e1="DDI-PubMed.23712757.s18.e1" e2="DDI-PubMed.23712757.s18.e3" /><pair ddi="false" e1="DDI-PubMed.23712757.s18.e1" e2="DDI-PubMed.23712757.s18.e4" /><pair ddi="false" e1="DDI-PubMed.23712757.s18.e1" e2="DDI-PubMed.23712757.s18.e5" /><pair ddi="false" e1="DDI-PubMed.23712757.s18.e2" e2="DDI-PubMed.23712757.s18.e2" /><pair ddi="false" e1="DDI-PubMed.23712757.s18.e2" e2="DDI-PubMed.23712757.s18.e3" /><pair ddi="false" e1="DDI-PubMed.23712757.s18.e2" e2="DDI-PubMed.23712757.s18.e4" /><pair ddi="false" e1="DDI-PubMed.23712757.s18.e2" e2="DDI-PubMed.23712757.s18.e5" /><pair ddi="false" e1="DDI-PubMed.23712757.s18.e3" e2="DDI-PubMed.23712757.s18.e3" /><pair ddi="false" e1="DDI-PubMed.23712757.s18.e3" e2="DDI-PubMed.23712757.s18.e4" /><pair ddi="false" e1="DDI-PubMed.23712757.s18.e3" e2="DDI-PubMed.23712757.s18.e5" /><pair ddi="false" e1="DDI-PubMed.23712757.s18.e4" e2="DDI-PubMed.23712757.s18.e4" /><pair ddi="false" e1="DDI-PubMed.23712757.s18.e4" e2="DDI-PubMed.23712757.s18.e5" /></sentence><sentence text="22 (5" /><sentence text="42-9" /><sentence text="62), 13" /><sentence text="6 (11" /><sentence text="2-16" /><sentence text="6), and 22" /><sentence text="5 (17" /><sentence text="4-29" /><sentence text="3), respectively, for danoprevir, 1"><entity charOffset="22-32" id="DDI-PubMed.23712757.s27.e0" text="danoprevir" /></sentence><sentence text="97 (1" /><sentence text="72-2" /><sentence text="27), 2" /><sentence text="23 (2" /><sentence text="07-2" /><sentence text="42), and 2" /><sentence text="50 (2" /><sentence text="22-2" /><sentence text="81), respectively, for ritonavir, and 1"><entity charOffset="23-32" id="DDI-PubMed.23712757.s36.e0" text="ritonavir" /></sentence><sentence text="42 (1" /><sentence text="29-1" /><sentence text="57), 3" /><sentence text="65 (3" /><sentence text="27-4" /><sentence text="08), and 6" /><sentence text="15 (5" /><sentence text="32-7" /><sentence text="11), respectively, for ciclosporin"><entity charOffset="23-34" id="DDI-PubMed.23712757.s45.e0" text="ciclosporin" /></sentence><sentence text=" All treatments were well tolerated, with no laboratory abnormalities, and no clinically significant changes in vital signs, electrocardiograms, or physical examinations observed" /><sentence text="" /><sentence text="A significant drug-drug interaction was observed between ciclosporin and danoprevir/ritonavir, leading to substantial increases in exposure to danoprevir and a lesser impact on exposure to ritonavir"><entity charOffset="57-68" id="DDI-PubMed.23712757.s48.e0" text="ciclosporin" /><entity charOffset="73-83" id="DDI-PubMed.23712757.s48.e1" text="danoprevir" /><entity charOffset="84-93" id="DDI-PubMed.23712757.s48.e2" text="ritonavir" /><entity charOffset="189-198" id="DDI-PubMed.23712757.s48.e3" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.23712757.s48.e0" e2="DDI-PubMed.23712757.s48.e0" /><pair ddi="false" e1="DDI-PubMed.23712757.s48.e0" e2="DDI-PubMed.23712757.s48.e1" /><pair ddi="false" e1="DDI-PubMed.23712757.s48.e0" e2="DDI-PubMed.23712757.s48.e2" /><pair ddi="false" e1="DDI-PubMed.23712757.s48.e0" e2="DDI-PubMed.23712757.s48.e3" /><pair ddi="false" e1="DDI-PubMed.23712757.s48.e1" e2="DDI-PubMed.23712757.s48.e1" /><pair ddi="false" e1="DDI-PubMed.23712757.s48.e1" e2="DDI-PubMed.23712757.s48.e2" /><pair ddi="false" e1="DDI-PubMed.23712757.s48.e1" e2="DDI-PubMed.23712757.s48.e3" /><pair ddi="false" e1="DDI-PubMed.23712757.s48.e2" e2="DDI-PubMed.23712757.s48.e2" /><pair ddi="false" e1="DDI-PubMed.23712757.s48.e2" e2="DDI-PubMed.23712757.s48.e3" /></sentence><sentence text=" Therefore, co-administration of danoprevir/ritonavir with potent OATP inhibitors should be undertaken with appropriate precautions"><entity charOffset="33-43" id="DDI-PubMed.23712757.s49.e0" text="danoprevir" /><entity charOffset="44-53" id="DDI-PubMed.23712757.s49.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.23712757.s49.e0" e2="DDI-PubMed.23712757.s49.e0" /><pair ddi="false" e1="DDI-PubMed.23712757.s49.e0" e2="DDI-PubMed.23712757.s49.e1" /></sentence><sentence text="" /></document>